TESARO (NASDAQ:TSRO) Earns Daily Media Impact Score of 0.13

News articles about TESARO (NASDAQ:TSRO) have trended somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TESARO earned a news impact score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.8110412811373 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

TESARO (NASDAQ:TSRO) traded down $1.09 on Friday, hitting $82.87. The stock had a trading volume of 486,683 shares, compared to its average volume of 719,052. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $4,565.91, a PE ratio of -9.82 and a beta of 1.52. TESARO has a 1-year low of $76.13 and a 1-year high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. TESARO’s quarterly revenue was up 740.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.72) EPS. analysts anticipate that TESARO will post -8.18 earnings per share for the current year.

Several equities research analysts have recently issued reports on TSRO shares. HC Wainwright reiterated a “buy” rating and set a $158.00 price target on shares of TESARO in a report on Thursday, October 26th. Citigroup reissued a “buy” rating and issued a $216.00 price objective on shares of TESARO in a research note on Monday, September 11th. Oppenheimer reissued a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research note on Sunday, September 10th. Cann reissued a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research note on Friday, September 8th. Finally, Lake Street Capital reissued a “buy” rating and issued a $143.00 price objective on shares of TESARO in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $156.01.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. 40.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://weekherald.com/2017/12/30/tesaro-tsro-receives-news-sentiment-score-of-0-13.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply